Arvin A M, Pollard R B, Rasmussen L E, Merigan T C
J Clin Invest. 1980 Apr;65(4):869-78. doi: 10.1172/JCI109739.
86 patients with lymphoma were evaluated prospectively for clinical and laboratory evidence of recurrent varicella-zoster, herpes simplex, and cytomegalovirus infections during the first 16 mo of treatment. Cellular immunity to the viral antigens was measured by in vitro lymphocyte transformation and interferon production. Antibody titers and nonspecific measures of cellular immunity, including T-cell quantitation and transformation to phytohemagglutinin, were also assessed. The patients treated with radiation and chemotherapy had the highest incidence of reactivation of each of the viruses (15-19%). Greater susceptibility to herpes viral reactivation in these patients correlated with suppression of cell-mediated immunity to the specific virus. In individual patients, suppression of cellular immunity to the specific herpes viral antigen preceded each episode of reactivation, but recurrent infection did not occur in all patients with diminished specific lymphocyte transformation. Absence of the response appears to be a necessary but not a sufficient condition for the recrudescence of latent infection. Better preservation of cellular immunity to herpes simplex antigen during treatment was associated with infrequent reactivation of herpes simplex. In 25 patients with acute herpes zoster, uncomplicated recovery from the infection was accompanied by the development of lymphocyte transformation and interferon production to varicella-zoster antigen. Quantitation of T-cell numbers and phytohemagglutinin transformation did not correlate with the presence of viral cellular immunity in treated patients. Responses returned while T-cell numbers were low, and the recovery of phytohemagglutinin transformation often preceded recovery of the responses to viral antigens. Although some patients had deficiencies in viral cellular immunity at diagnosis, the duration of the suppression of specific antiviral responses resulting from treatment appears to be the most important factor predisposing to the recurrence of herpes infections in lymphoma patients.
对86例淋巴瘤患者进行前瞻性评估,观察其在治疗的前16个月期间复发性水痘 - 带状疱疹、单纯疱疹和巨细胞病毒感染的临床及实验室证据。通过体外淋巴细胞转化和干扰素产生来检测对病毒抗原的细胞免疫。还评估了抗体滴度以及细胞免疫的非特异性指标,包括T细胞定量和对植物血凝素的转化。接受放疗和化疗的患者每种病毒再激活的发生率最高(15 - 19%)。这些患者对疱疹病毒再激活的易感性增加与对特定病毒的细胞介导免疫抑制相关。在个体患者中,对特定疱疹病毒抗原的细胞免疫抑制先于每次再激活发作,但并非所有特异性淋巴细胞转化降低的患者都会发生反复感染。无反应似乎是潜伏感染复发的必要但非充分条件。治疗期间对单纯疱疹抗原的细胞免疫保存较好与单纯疱疹再激活不频繁相关。在25例急性带状疱疹患者中,感染的顺利恢复伴随着对水痘 - 带状疱疹抗原的淋巴细胞转化和干扰素产生的发展。T细胞数量定量和植物血凝素转化与治疗患者中病毒细胞免疫的存在无关。在T细胞数量较低时反应恢复,植物血凝素转化的恢复通常先于对病毒抗原反应的恢复。尽管一些患者在诊断时存在病毒细胞免疫缺陷,但治疗导致的特异性抗病毒反应抑制持续时间似乎是淋巴瘤患者疱疹感染复发的最重要易感因素。